Bioanalysis publishes special focus issue on anti-doping
Bioanalysis publishes special focus issue on anti-doping analysis and the Olympics
Bioanalysis has published a special focus issue on anti-doping analysis and the Olympics, highlighting the journal’s dedication to ensure timely and relevant coverage.
The issue is guest edited by two high-profile experts: Dr Olivier Rabin (World Anti-Doping Agency) and Dr Patrick Schamasch (International Olympic Committee), as well as contributions from an array of experts from both academia and industry who are highly specialized in the field of anti-doping.
As Dr Rabin and Dr Schamasch explain, “The articles contained within this special Olympic issue of Bioanalysis offer an insight into the challenges faced by the anti-doping analysts in the testing procedures of athletes’ samples, and examine some of the recent developments made in the science of anti-doping as well as some future perspectives in anti-doping testing.”
This special focus will cover areas such as the history of doping analysis and the World Anti-Doping Agency, the current state of the field – including the challenges faced in implementing the Athlete Biological Passport, the use of performance-enhancing drugs such as EPO and peptides and the difficulty in maintaining a balance between regulatory bodies and laboratory approval – as well as providing a detailed outlook into the future of this field with respect to new technologies, testing matrices and doping agents.
The issue features a range of absorbing articles from Perspectives to Reviews, Special Reports and Editorials, as well as an insightful Interview with the academic and industry leaders of the London 2012 anti-doping laboratory: Prof. David Cowan (King’s College London) and Dr Campbell Barker (GlaxoSmithKline), who detail the implications and challenges of forming such a unique and novel partnership.
“Doping amongst athletes is an ongoing issue which continues to threaten the integrity of sport and the health of those who cheat this way in order to gain an unfair advantage,” conclude Dr Rabin and Dr Schamasch. “Part of WADA’s role is to keep the scientific community informed of, and involved in, the anti-doping issue so that it remains a priority in terms of sport and wider society.”
A full list of all the articles included in this issue can be found at: http://www.future-science.com/toc/bio/4/13
If you are interested in receiving a free 30-day online trial to evaluate the journal’s content please contact firstname.lastname@example.org, quoting BIO0612.
For further information on Bioanalysis, please contact the Editor, Ryan De Vooght-Johnson (email@example.com).
Bioanalysis addresses the sensitive analytical techniques used for the study of drugs, metabolites and biomarkers in the development of (bio)pharmaceuticals, as well as allied fields including forensics, toxicology and anti-doping. The journal, published by Future Science Ltd and launched in April 2009, is published on a fortnightly basis (24 issues per year) and indexed by Medline® and ISI, with an impact factor of 1.337 (2010). The journal also forms the hub of the interactive community website – Bioanalysis Zone – providing principle content plus an online forum and wider access to news, research, jobs, webinars, events and more.
ABOUT FUTURE SCIENCE GROUP
The Future Science Group (www.future-science-group.com) is an expanding group of independent publishing companies active in the field of scientific information and endeavor, including Expert Reviews Ltd (formerly known as Future Drugs Ltd) Future Medicine Ltd and Future Science Ltd. As a leading provider of products and services for the medical, science and business communities, we present the most important scientific breakthroughs in an accessible and evaluated format, while at the same time providing the scientific community with unique vehicles for disseminating forward-thinking research information and data. Complete listings of titles under each imprint are available at www.expert-reviews.com, www.futuremedicine.com and www.future-science.com.